The efficacy and safety of apatinib in Ewing’s sarcoma: a retrospective analysis in one institution

References

• RosenGWollnerNTanCProceedings: disease-free survival in children with Ewing’s sarcoma treated with radiation therapy and adjuvant four-drug sequential chemotherapyCancer19743323843934812758
   PubMed Web of Science ®Google Scholar
• BurchillSAMolecular abnormalities in Ewing’s sarcomaExpert Rev Anticancer Ther20088101675168718925858
   PubMed Web of Science ®Google Scholar
• JiangYLudwigJJankuFTargeted therapies for advanced Ewing sarcoma family of tumorsCancer Treat Rev201541539140025869102
   PubMed Web of Science ®Google Scholar
• EsiashviliNGoodmanMMarcusRBChanges in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results dataJ Pediatr Hematol Oncol200830642543018525458
   PubMed Web of Science ®Google Scholar
• KrasinMJDavidoffAMRodriguez-GalindoCDefinitive surgery and multiagent systemic therapy for patients with localized Ewing sarcoma family of tumors: local outcome and prognostic factorsCancer2005104236737315948159
   PubMed Web of Science ®Google Scholar
• CotterillSJAhrensSPaulussenMPrognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study GroupJ Clin Oncol200018173108311410963639
   PubMed Web of Science ®Google Scholar
• van MaldegemAMBensonCRutkowskiPEtoposide and carbo- or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective studyPediatr Blood Cancer2015621404425251256
   PubMed Web of Science ®Google Scholar
• FoxEPatelSWathenJKPhase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003Oncologist201217332122363068
   PubMed Web of Science ®Google Scholar
• RaciborskaABilskaKDrabkoKVincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcomaPediatr Blood Cancer201360101621162523776128
   PubMed Web of Science ®Google Scholar
• ArpaciEYetisyigitTSekerMPrognostic factors and clinical outcome of patients with Ewing’s sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical OncologyMed Oncol201330146923345116
   PubMed Web of Science ®Google Scholar
• LiJZhaoXChenLSafety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignanciesBMC Cancer20101052920923544
   PubMed Web of Science ®Google Scholar
• DingJChenXGaoZMetabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humansDrug Metab Dispos20134161195121023509226
   PubMed Web of Science ®Google Scholar
• LiJQinSXuJRandomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctionJ Clin Oncol201634131448145426884585
   PubMed Web of Science ®Google Scholar
• JiGHongLYangPSuccessful treatment of angiosarcoma of the scalp with apatinib: a case reportOnco Targets Ther201694989499227563253
   PubMed Web of Science ®Google Scholar
• JiGHongLYangPSuccessful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib: a case reportOnco Targets Ther201694989499227563253
   PubMed Web of Science ®Google Scholar
• TaylorPTHaverstickDRe: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)J Natl Cancer Inst200597215115657346
   PubMedGoogle Scholar
• XieLGuoWWangYYanTJiTXuJApatinib for advanced sarcoma: results from multiple institutions’ off-label use in ChinaBMC Cancer201818139629625604
   PubMed Web of Science ®Google Scholar
• de RojasTBautistaFJMaderoLMorenoLThe first step to integrating adapted common terminology criteria for adverse events for childrenJ Clin Oncol201634182196219727114600
   PubMed Web of Science ®Google Scholar
• AhmedAAZiaHWagnerLTherapy resistance mechanisms in Ewing’s sarcoma family tumorsCancer Chemother Pharmacol201473465766324469502
   PubMed Web of Science ®Google Scholar
• VornicovaOBar-SelaGInvestigational therapies for Ewing sarcoma: a search without a clear findingExpert Opin Investig Drugs2016256679686
   PubMed Web of Science ®Google Scholar
• ArnaldezFIHelmanLJNew strategies in Ewing sarcoma: lost in translation?Clin Cancer Res201420123050305624756371
   PubMed Web of Science ®Google Scholar
• NaingALorussoPFuSInsulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing’s sarcoma family tumorsClin Cancer Res20121892625263122465830
   PubMed Web of Science ®Google Scholar
• YudohKKanamoriMOhmoriKYasudaTAokiMKimuraTConcentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomasBr J Cancer200184121610161511401313
   PubMed Web of Science ®Google Scholar
• YudohKKanamoriMOhmoriKYasudaTAokiMKimuraTConcentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomasBr J Cancer200184121610161511401313
   PubMed Web of Science ®Google Scholar
• DalalSBerryAMCullinaneCJVascular endothelial growth factor: a therapeutic target for tumors of the Ewing’s sarcoma familyClin Cancer Res20051162364237815788688
   PubMed Web of Science ®Google Scholar
• ZhouZBolontradeMFReddyKSuppression of Ewing’s sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapyClin Cancer Res200713164867487317699866
   PubMed Web of Science ®Google Scholar
• AhmedAAShermanAKPawelBRExpression of therapeutic targets in Ewing sarcoma family tumorsHum Pathol20124371077108322196127
   PubMed Web of Science ®Google Scholar
• KreuterMPaulussenMBoeckelerJClinical significance of vascular endothelial growth factor-A expression in Ewing’s sarcomaEur J Cancer200642121904191116824746
   PubMed Web of Science ®Google Scholar
• AutieroMWaltenbergerJCommuniDRole of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1Nat Med20039793694312796773
   PubMed Web of Science ®Google Scholar
• ZhuBLiJXieQDiaoLGaiLYangWEfficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: an observational studyCancer Biol Ther201819319820429261005
   PubMed Web of Science ®Google Scholar
• WangYBiMZhangHGaoZZhouHChangSApatinib in gastric carcinoma: a case report of partial response for first-line treatment in advanced diseaseAsia Pac J Clin Oncol2017135e528e53028028915
   PubMed Web of Science ®Google Scholar
• DongMBiJLiuXWangBWangJSignificant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: a case reportMedicine20169531e436827495042
   PubMed Web of Science ®Google Scholar
• LiJWangLEfficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinomaOnco Targets Ther2017103965396928860804
   PubMed Web of Science ®Google Scholar